Susan K Seo
Overview
Explore the profile of Susan K Seo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
3172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avutu V, Algazaq J, Seier K, Desir-Camille R, Qin L, Babatunde O, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39993596
Adoptive cellular therapy (ACT) is an increasingly widely used treatment approach for malignancy. While infectious complications of ACT have been well described in patients with hematologic malignancies, limited data are...
2.
Schleimer L, Hakki L, Seier K, Seo S, Cohen N, Usiak S, et al.
Ann Surg Oncol
. 2024 Dec;
32(4):2505-2506.
PMID: 39692984
No abstract available.
3.
Schleimer L, Hakki L, Seier K, Seo S, Cohen N, Usiak S, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):1043-1053.
PMID: 39570297
Background: Surgical site infections (SSIs) are a major driver of morbidity after combined liver and colorectal surgery for metastatic colorectal cancer. Available literature is inadequate to characterize risk factors and...
4.
Baden L, Swaminathan S, Almyroudis N, Angarone M, Baluch A, Barros N, et al.
J Natl Compr Canc Netw
. 2024 Nov;
22(9):617-644.
PMID: 39536464
There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. Several risk factors can predispose these patients to infectious complications. Some such...
5.
Melica G, Luna de Abia A, Shah G, Devlin S, Corona M, Fein J, et al.
Transplant Cell Ther
. 2024 Oct;
31(1):36-44.
PMID: 39448032
Patients undergoing CD19 chimeric antigen receptor (CAR)-T cell therapy exhibit multiple immune deficits that may increase their susceptibility to infections. Invasive fungal infections (IFIs) are life-threatening events in the setting...
6.
Pandey S, Wisniewski R, Newman T, Seo S, Rosa W
Lancet
. 2024 Sep;
404(10457):1015.
PMID: 39277284
No abstract available.
7.
Shahid Z, Jain T, Dioverti V, Pennisi M, Mikkilineni L, Thiruvengadam S, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):955-969.
PMID: 39084261
Chimeric antigen receptor (CAR) T-cell therapy is rapidly advancing, offering promising treatments for patients with hematological malignancy. However, associated infectious complications remain a significant concern because of their contribution to...
8.
Tan C, Palen L, Su Y, Li Y, Gennarelli R, Perales M, et al.
Transplant Cell Ther
. 2024 Jun;
30(8):792.e1-792.e12.
PMID: 38838781
Preemptive therapy (PET) historically has been the primary strategy to reduce early-onset cytomegalovirus (CMV) reactivation after allogeneic hematopoietic cell transplantation (HCT) but is associated with antiviral-associated toxicities and increases in...
9.
Lin A, Brown S, Chinapen S, Lee Y, Seo S, Ponce D, et al.
Blood Adv
. 2023 Oct;
7(23):7153-7160.
PMID: 37906513
Reactivation of latent cytomegalovirus (CMV) is increased in recipients of allogeneic hematopoietic cell transplantation (allo-HCT) with seropositive CMV using posttransplant cyclophosphamide (PT-Cy)-based graft-versus-host disease (GVHD) prophylaxis. Letermovir, a novel DNA...
10.
El Chaer F, Kaul D, Englund J, Boeckh M, Batista M, Seo S, et al.
Transplant Cell Ther
. 2023 Oct;
29(12):730-738.
PMID: 37783338
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update the 2009 compendium-style infectious...